Therapeutic potential of extracellular vesicles in preclinical stroke models: a systematic review and meta-analysisTherapeutic potential of extracellular vesicles in preclinical stroke models: a systematic review and meta-analysis

Abstract

ObjectivesCurrently there is a paucity of clinically available regenerative therapies for stroke. Extracellular vesicles (EV) have been investigated for their potential as modulators of regeneration in the poststroke brain. This systematic review and meta-analysis aims to provide a summary of the efficacy of therapeutic EVs in preclinical stroke models, to inform future research in this emerging field.MethodsStudies were identified by a comprehensive literature search of two online sources and subsequent screening. Studies using lesion volume or neurological score as outcome measures were included. Standardised mean difference (SMD) and 95% CIs were calculated using a restricted maximum likelihood random effects model. Publication bias was assessed with Egger’s regression and presented as funnel plots with trim and fill analysis. Subgroup analysis was performed to assess the effects of different study variables. Study quality and risk of bias were assessed using the CAMARADES checklist.ResultsA total of 20 publications were included in the systematic review, of which 19 were assessed in the meta-analysis (43 comparisons). Overall, EV interventions improved lesion volume (SMD: −1.95, 95% CI −2.72 to 1.18) and neurological scores (SMD: −1.26, 95% CI −1.64 to 0.87) compared with control groups. Funnel plots were asymmetrical suggesting publication bias, and trim and fill analysis predicted seven missing studies for lesion volume. Subgroup analysis suggested administration at 0–23 hours after stroke was the most effective timepoint for EV treatment. The median score on the CAMARADES checklist was 7 (IQR: 5–8).ConclusionsEVs may offer a promising new avenue for stroke therapies, as EV-based interventions had positive impacts on lesion volume and neurological score in preclinical stroke models.PROSPERO registration numberCRD42019134925.

Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies

“…The calculated effect size was similar to the therapeutic potential of other approaches in the field, such as the delivery of therapeutic molecules via extracellular vesicles (-1.95 [-2.72, -1.18]) 61 or intraparenchymal transplantation of neural stem/progenitor cells (-1.11 [-1.5, -0.73]). 62 Due to the high heterogeneity of the analyzed studies, we hoped to learn more about determinants of the effect size by subgroup analysis.…”

Neurogenesis After Stroke: A Therapeutic Perspective

“…A recent systemic review highlighted the therapeutic potential of extracellular vesicles secreted by various cells like MSCs, macrophages, and neural stem cells, identifying these vesicles as an attractive approach. However, being a recent trend, there is a significant amount of heterogeneity among the results of applications, presumably due to isolation and administration techniques, as well as cell-type of origin [140]. Further work on MSCs preconditioning with various inflammatory mediators found that IL-1α can be used as a key priming stimulus to induce MSCs to produce anti-inflammatory and neurotrophic factors [141], and a further in vivo study in mice demonstrated that conditioned medium of IL-1α-primed MSCs administered peripherally after stroke had beneficial effects on stroke outcome and functional recovery [139].…”

Effects of extracellular vesicles for ischemic stroke: A meta‑analysis of preclinical studies

“…In summary, extracellular vesicle therapy is a promising research direction for ischemic stroke. Previous research has demonstrated the positive efficacy of extracellular vesicles on infarct volume and neurological score in stroke models (33). Recently, cell-derived extracellular vesicles have been widely used in preclinical trials of ischemic stroke.…”